Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2016

08.02.2016 | Gynecologic Oncology

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node

verfasst von: Linn Woelber, MD, Christine Eulenburg, PhD, Donata Grimm, MD, Fabian Trillsch, MD, Inga Bohlmann, MD, Eike Burandt, MD, Jan Dieckmann, MD, Susanne Klutmann, MD, Barbara Schmalfeldt, MD, Sven Mahner, MD, Katharina Prieske, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

In patients with primary vulvar cancer and bilateral sentinel lymph node (SLN) biopsy, bilateral complete inguino-femoral lymphadenectomy (LAE) is recommended, even in cases with only unilaterally positive SLN by most guidelines. The risk of contralateral non-SLN metastasis is unclear.

Methods

All patients with primary vulvar cancer receiving an SLN dissection with radioactive tracer ± blue dye at the University Medical Center Hamburg-Eppendorf between 2001 and 2013 were retrospectively evaluated. Median follow-up was 33 months.

Results

A total of 140 patients were included; 124 with bilateral and 16 with unilateral SLN dissection. A median number of two SLNs (range 1–7) per groin were dissected. Overall, 53 (53/140, 37.9 %) patients received a complete inguino-femoral LAE, 41 of whom (77.4 %) had previously presented with a positive SLN (33 unilaterally, 8 bilaterally). Of the 33 patients with unilaterally positive SLN, 28 (84.9 %) underwent complete bilateral inguino-femoral LAE despite a contralateral negative SLN. Of these patients, none presented a contralateral non-SLN metastasis (0/28, 0 %) in full dissection; however, one developed groin recurrence in the initially SLN-negative, fully dissected groin after 19 months (1/28, 3.6 %).

Conclusion

In case of bilateral SLN biopsy for clinically node-negative disease and only unilaterally positive SLN, the risk for contralateral non-SLN metastases appears to be low. These data support the omission of contralateral LAE to reduce surgical morbidity.
Literatur
1.
Zurück zum Zitat Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: The AGO-CaRE-1 Study. J Natl Cancer Inst. 2015;107:dju426. Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: The AGO-CaRE-1 Study. J Natl Cancer Inst. 2015;107:dju426.
2.
Zurück zum Zitat Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26:884–9.CrossRefPubMed Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26:884–9.CrossRefPubMed
3.
Zurück zum Zitat Burke TW, Levenback C, Coleman RL, et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995;57:215–20.CrossRefPubMed Burke TW, Levenback C, Coleman RL, et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995;57:215–20.CrossRefPubMed
4.
Zurück zum Zitat Katz A, Eifel PJ, Jhingran A, Levenback CF. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003;57:409–18.CrossRefPubMed Katz A, Eifel PJ, Jhingran A, Levenback CF. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003;57:409–18.CrossRefPubMed
5.
Zurück zum Zitat National German Guideline S2k (2015) Diagnosis, therapy, and follow-up care of vulvar cancer and its precursors. AWMF Registry No. 015/059. National German Guideline S2k (2015) Diagnosis, therapy, and follow-up care of vulvar cancer and its precursors. AWMF Registry No. 015/059.
6.
Zurück zum Zitat Hinten F, van den Einden LC, Hendriks JC, et al. Risk factors for short- and long-term complications after groin surgery in vulvar cancer. Br J Cancer. 2011;105:1279–87.CrossRefPubMedPubMedCentral Hinten F, van den Einden LC, Hendriks JC, et al. Risk factors for short- and long-term complications after groin surgery in vulvar cancer. Br J Cancer. 2011;105:1279–87.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Magrina JF, Webb MJ, Gaffey TA, Symmonds RE. Stage I squamous cell cancer of the vulva. Am J Obstet Gynecol. 1979;134:453–9.PubMed Magrina JF, Webb MJ, Gaffey TA, Symmonds RE. Stage I squamous cell cancer of the vulva. Am J Obstet Gynecol. 1979;134:453–9.PubMed
9.
Zurück zum Zitat Hoffman MS, Roberts WS, Finan MA, et al. A comparative study of radical vulvectomy and modified radical vulvectomy for the treatment of invasive squamous cell carcinoma of the vulva. Gynecol Oncol. 1992;45:192–7.CrossRefPubMed Hoffman MS, Roberts WS, Finan MA, et al. A comparative study of radical vulvectomy and modified radical vulvectomy for the treatment of invasive squamous cell carcinoma of the vulva. Gynecol Oncol. 1992;45:192–7.CrossRefPubMed
10.
Zurück zum Zitat Hacker NF, Berek JS, Lagasse LD, et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol. 1983;61:408–12.PubMed Hacker NF, Berek JS, Lagasse LD, et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol. 1983;61:408–12.PubMed
11.
Zurück zum Zitat Andrews SJ, Williams BT, DePriest PD, et al. Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva. Gynecol Oncol. 1994;55:41–46.CrossRefPubMed Andrews SJ, Williams BT, DePriest PD, et al. Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva. Gynecol Oncol. 1994;55:41–46.CrossRefPubMed
12.
Zurück zum Zitat Hacker NF, Berek JS, Lagasse LD, et al. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol. 1984;63:155–62.PubMed Hacker NF, Berek JS, Lagasse LD, et al. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol. 1984;63:155–62.PubMed
13.
Zurück zum Zitat Jeppesen JT, Sell A, Skjoldborg H. Treatment of cancer of the vulva. Acta Obstet Gynecol Scand. 1972;51:101–7.CrossRefPubMed Jeppesen JT, Sell A, Skjoldborg H. Treatment of cancer of the vulva. Acta Obstet Gynecol Scand. 1972;51:101–7.CrossRefPubMed
14.
Zurück zum Zitat Rutledge F, Smith JP, Franklin EW. Carcinoma of the vulva. Am J Obstet Gynecol. 1970;106:1117–30.CrossRefPubMed Rutledge F, Smith JP, Franklin EW. Carcinoma of the vulva. Am J Obstet Gynecol. 1970;106:1117–30.CrossRefPubMed
15.
Zurück zum Zitat Krupp PJ, Bohm JW. Lymph gland metastases in invasive squamous cell cancer of the vulva. Am J Obstet Gynecol. 1978;130:943–52.CrossRefPubMed Krupp PJ, Bohm JW. Lymph gland metastases in invasive squamous cell cancer of the vulva. Am J Obstet Gynecol. 1978;130:943–52.CrossRefPubMed
16.
Zurück zum Zitat Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecol Oncol. 2007;105:742–6. Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecol Oncol. 2007;105:742–6.
17.
Zurück zum Zitat Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S7–27.CrossRefPubMed Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S7–27.CrossRefPubMed
18.
Zurück zum Zitat Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–262.CrossRefPubMed Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–262.CrossRefPubMed
19.
Zurück zum Zitat Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1992;24:389–96.CrossRefPubMed Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1992;24:389–96.CrossRefPubMed
20.
Zurück zum Zitat Cormio G, Loizzi V, Carriero C, et al. Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl). 2010;19:302–7.CrossRef Cormio G, Loizzi V, Carriero C, et al. Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl). 2010;19:302–7.CrossRef
21.
Zurück zum Zitat Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992;79:490–7.PubMed Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992;79:490–7.PubMed
Metadaten
Titel
The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node
verfasst von
Linn Woelber, MD
Christine Eulenburg, PhD
Donata Grimm, MD
Fabian Trillsch, MD
Inga Bohlmann, MD
Eike Burandt, MD
Jan Dieckmann, MD
Susanne Klutmann, MD
Barbara Schmalfeldt, MD
Sven Mahner, MD
Katharina Prieske, MD
Publikationsdatum
08.02.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5114-6

Weitere Artikel der Ausgabe 8/2016

Annals of Surgical Oncology 8/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.